Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study

Susy M. Scholl, Rosette Lidereau, Anne De La Rochefordière, Christine Cohen Solal Le-Nir, Véronique Mosseri, Catherine Noguès, Pierre Pouillart, E. Richard Stanley

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Earlier results, suggesting an autocrine tumor cell stimulation by CSF-1, are in agreement with data by Fildermann et al., showing an enhanced motility and invasiveness in the CSF-1 receptor expressing BT20 breast cancer cell line upon stimulation with recombinant CSF-1. Tumor-cell secreted CSF-1 has also been shown to cause monocyte recruitment, but not cytotoxicity. Down-regulation of monocyte class II antigen expression after exposure to high concentrations of CSF-1 may decrease macrophage-mediated tumor cytotoxicity and favor tolerance. Raised CSF-1 serum levels may thus increase tumor metastatic behavior as well as cause immune suppression in advanced stage disease. We set out to evaluate serum CSF-1 levels in primary and metastatic breast cancer. Serum samples from one hundred and eighteen primary breast cancer patients and seventy-five patients with metastatic disease were assayed by radio-immune-assay (RIA) for circulating colony-stimulating factor 1. Mean serum levels were significantly higher in the metastatic population (9.7 ng/ml ± 0.8) as compared to the patients with primary tumors (4.2 ± 0.2) (p = 0.0001). Patients with early stage tumors (T0/T1/T2) had significantly lower levels than patients with tumors of larger size (T3/T4) (p = 0.0001). Relapse and survival statistics were analyzed using Kaplan-Meier estimates. Samples from 118 primary breast cancer patients were available to study. The median follow up was 85 months (range: 1-108). An elevated CSF-1 concentration (> 6.6 ng/ml or > 550 Units/ml) was associated with a shorter disease free interval (p = 0.03). In a multivariate analysis, including T (clinical tumor size), N (clinical node status), histological grade, and hormone receptor status, CSF-1 remained significantly associated with a poorer outcome (relative risk of relapse: RR: 3.3 [1.3-8.5]), together with tumor size (RR: 2.8 [1-8.2]) and clinically involved nodes (RR: 4.1 [2.1-8]). These results were not modified following adjustment for type of treatment. We conclude that raised circulating CSF-1 levels may be an indicator of early metastatic relapse.

Original languageEnglish (US)
Pages (from-to)275-283
Number of pages9
JournalBreast Cancer Research and Treatment
Volume39
Issue number3
StatePublished - 1996

Fingerprint

Macrophage Colony-Stimulating Factor
Breast Neoplasms
Neoplasms
Macrophage Colony-Stimulating Factor Receptors
Serum
Recurrence
Monocytes
Histocompatibility Antigens Class II
Kaplan-Meier Estimate
Radio
Down-Regulation
Multivariate Analysis
Macrophages
Hormones
Cell Line
Survival

Keywords

  • Breast cancer
  • CSF-1
  • Cytokines
  • Metastasis
  • Prognosis
  • Serum markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Scholl, S. M., Lidereau, R., De La Rochefordière, A., Le-Nir, C. C. S., Mosseri, V., Noguès, C., ... Stanley, E. R. (1996). Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Research and Treatment, 39(3), 275-283.

Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. / Scholl, Susy M.; Lidereau, Rosette; De La Rochefordière, Anne; Le-Nir, Christine Cohen Solal; Mosseri, Véronique; Noguès, Catherine; Pouillart, Pierre; Stanley, E. Richard.

In: Breast Cancer Research and Treatment, Vol. 39, No. 3, 1996, p. 275-283.

Research output: Contribution to journalArticle

Scholl, SM, Lidereau, R, De La Rochefordière, A, Le-Nir, CCS, Mosseri, V, Noguès, C, Pouillart, P & Stanley, ER 1996, 'Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study', Breast Cancer Research and Treatment, vol. 39, no. 3, pp. 275-283.
Scholl, Susy M. ; Lidereau, Rosette ; De La Rochefordière, Anne ; Le-Nir, Christine Cohen Solal ; Mosseri, Véronique ; Noguès, Catherine ; Pouillart, Pierre ; Stanley, E. Richard. / Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. In: Breast Cancer Research and Treatment. 1996 ; Vol. 39, No. 3. pp. 275-283.
@article{25664bc9e1cc4824a5c7302a3a4cd8d2,
title = "Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study",
abstract = "Earlier results, suggesting an autocrine tumor cell stimulation by CSF-1, are in agreement with data by Fildermann et al., showing an enhanced motility and invasiveness in the CSF-1 receptor expressing BT20 breast cancer cell line upon stimulation with recombinant CSF-1. Tumor-cell secreted CSF-1 has also been shown to cause monocyte recruitment, but not cytotoxicity. Down-regulation of monocyte class II antigen expression after exposure to high concentrations of CSF-1 may decrease macrophage-mediated tumor cytotoxicity and favor tolerance. Raised CSF-1 serum levels may thus increase tumor metastatic behavior as well as cause immune suppression in advanced stage disease. We set out to evaluate serum CSF-1 levels in primary and metastatic breast cancer. Serum samples from one hundred and eighteen primary breast cancer patients and seventy-five patients with metastatic disease were assayed by radio-immune-assay (RIA) for circulating colony-stimulating factor 1. Mean serum levels were significantly higher in the metastatic population (9.7 ng/ml ± 0.8) as compared to the patients with primary tumors (4.2 ± 0.2) (p = 0.0001). Patients with early stage tumors (T0/T1/T2) had significantly lower levels than patients with tumors of larger size (T3/T4) (p = 0.0001). Relapse and survival statistics were analyzed using Kaplan-Meier estimates. Samples from 118 primary breast cancer patients were available to study. The median follow up was 85 months (range: 1-108). An elevated CSF-1 concentration (> 6.6 ng/ml or > 550 Units/ml) was associated with a shorter disease free interval (p = 0.03). In a multivariate analysis, including T (clinical tumor size), N (clinical node status), histological grade, and hormone receptor status, CSF-1 remained significantly associated with a poorer outcome (relative risk of relapse: RR: 3.3 [1.3-8.5]), together with tumor size (RR: 2.8 [1-8.2]) and clinically involved nodes (RR: 4.1 [2.1-8]). These results were not modified following adjustment for type of treatment. We conclude that raised circulating CSF-1 levels may be an indicator of early metastatic relapse.",
keywords = "Breast cancer, CSF-1, Cytokines, Metastasis, Prognosis, Serum markers",
author = "Scholl, {Susy M.} and Rosette Lidereau and {De La Rochefordi{\`e}re}, Anne and Le-Nir, {Christine Cohen Solal} and V{\'e}ronique Mosseri and Catherine Nogu{\`e}s and Pierre Pouillart and Stanley, {E. Richard}",
year = "1996",
language = "English (US)",
volume = "39",
pages = "275--283",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study

AU - Scholl, Susy M.

AU - Lidereau, Rosette

AU - De La Rochefordière, Anne

AU - Le-Nir, Christine Cohen Solal

AU - Mosseri, Véronique

AU - Noguès, Catherine

AU - Pouillart, Pierre

AU - Stanley, E. Richard

PY - 1996

Y1 - 1996

N2 - Earlier results, suggesting an autocrine tumor cell stimulation by CSF-1, are in agreement with data by Fildermann et al., showing an enhanced motility and invasiveness in the CSF-1 receptor expressing BT20 breast cancer cell line upon stimulation with recombinant CSF-1. Tumor-cell secreted CSF-1 has also been shown to cause monocyte recruitment, but not cytotoxicity. Down-regulation of monocyte class II antigen expression after exposure to high concentrations of CSF-1 may decrease macrophage-mediated tumor cytotoxicity and favor tolerance. Raised CSF-1 serum levels may thus increase tumor metastatic behavior as well as cause immune suppression in advanced stage disease. We set out to evaluate serum CSF-1 levels in primary and metastatic breast cancer. Serum samples from one hundred and eighteen primary breast cancer patients and seventy-five patients with metastatic disease were assayed by radio-immune-assay (RIA) for circulating colony-stimulating factor 1. Mean serum levels were significantly higher in the metastatic population (9.7 ng/ml ± 0.8) as compared to the patients with primary tumors (4.2 ± 0.2) (p = 0.0001). Patients with early stage tumors (T0/T1/T2) had significantly lower levels than patients with tumors of larger size (T3/T4) (p = 0.0001). Relapse and survival statistics were analyzed using Kaplan-Meier estimates. Samples from 118 primary breast cancer patients were available to study. The median follow up was 85 months (range: 1-108). An elevated CSF-1 concentration (> 6.6 ng/ml or > 550 Units/ml) was associated with a shorter disease free interval (p = 0.03). In a multivariate analysis, including T (clinical tumor size), N (clinical node status), histological grade, and hormone receptor status, CSF-1 remained significantly associated with a poorer outcome (relative risk of relapse: RR: 3.3 [1.3-8.5]), together with tumor size (RR: 2.8 [1-8.2]) and clinically involved nodes (RR: 4.1 [2.1-8]). These results were not modified following adjustment for type of treatment. We conclude that raised circulating CSF-1 levels may be an indicator of early metastatic relapse.

AB - Earlier results, suggesting an autocrine tumor cell stimulation by CSF-1, are in agreement with data by Fildermann et al., showing an enhanced motility and invasiveness in the CSF-1 receptor expressing BT20 breast cancer cell line upon stimulation with recombinant CSF-1. Tumor-cell secreted CSF-1 has also been shown to cause monocyte recruitment, but not cytotoxicity. Down-regulation of monocyte class II antigen expression after exposure to high concentrations of CSF-1 may decrease macrophage-mediated tumor cytotoxicity and favor tolerance. Raised CSF-1 serum levels may thus increase tumor metastatic behavior as well as cause immune suppression in advanced stage disease. We set out to evaluate serum CSF-1 levels in primary and metastatic breast cancer. Serum samples from one hundred and eighteen primary breast cancer patients and seventy-five patients with metastatic disease were assayed by radio-immune-assay (RIA) for circulating colony-stimulating factor 1. Mean serum levels were significantly higher in the metastatic population (9.7 ng/ml ± 0.8) as compared to the patients with primary tumors (4.2 ± 0.2) (p = 0.0001). Patients with early stage tumors (T0/T1/T2) had significantly lower levels than patients with tumors of larger size (T3/T4) (p = 0.0001). Relapse and survival statistics were analyzed using Kaplan-Meier estimates. Samples from 118 primary breast cancer patients were available to study. The median follow up was 85 months (range: 1-108). An elevated CSF-1 concentration (> 6.6 ng/ml or > 550 Units/ml) was associated with a shorter disease free interval (p = 0.03). In a multivariate analysis, including T (clinical tumor size), N (clinical node status), histological grade, and hormone receptor status, CSF-1 remained significantly associated with a poorer outcome (relative risk of relapse: RR: 3.3 [1.3-8.5]), together with tumor size (RR: 2.8 [1-8.2]) and clinically involved nodes (RR: 4.1 [2.1-8]). These results were not modified following adjustment for type of treatment. We conclude that raised circulating CSF-1 levels may be an indicator of early metastatic relapse.

KW - Breast cancer

KW - CSF-1

KW - Cytokines

KW - Metastasis

KW - Prognosis

KW - Serum markers

UR - http://www.scopus.com/inward/record.url?scp=0029737420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029737420&partnerID=8YFLogxK

M3 - Article

C2 - 8877007

AN - SCOPUS:0029737420

VL - 39

SP - 275

EP - 283

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -